Cambridge-based biologics company SolasCure has received authorisation to conduct clinical trials for its investigational product, Aurase Wound Gel, from the UK’s Medical and Healthcare products Regulatory Agency (MHRA) and approval to open its Investigational New Drug (IND) application by the FDA in the US.
SolasCure Ltd.
SolasCure’s mission is to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds.
Address :
Wellington House East Road Cambridge
Post Code: CB1 1BH
Country: United Kingdom
Website: https://solascure.com/
Membership Type: Corporate 6-20
There are no Products & Services to display
22-10-2021
Biotech start-up SolasCure has announced the completion of its Series A investment round, to support the development of its wound cleaning product, Aurase®. The Cambridge based biotech company has successfully completed its Series A raise of £15m, with funding from industry veterans, institutional ventures and strategic investors.
10-08-2021
There are no events to display
There are no jobs to display
By Dr Sam Bakri, Executive Chairman and CEO of biotech start-up, SolasCure
After more than 20 years in the life sciences industry, Dr Sam Bakri shares his journey as doctor-turned-entrepreneur of treating chronic wounds and mission to meet the unmet need.
06-09-2021
